IMDZ - Immune Design Corp.
| Previous Close | 5.84 |
| Open | 5.83 |
| Bid | 5.83 x 3000 |
| Ask | 5.85 x 4000 |
| Day's Range | 5.83 - 5.85 |
| 52 Week Range | 1.10 - 5.85 |
| Volume | 287,396 |
| Avg. Volume | 1,014,362 |
| Market Cap | 282.936M |
| Beta (3Y Monthly) | 4.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.14 |
| Earnings Date | May 15, 2018 - May 21, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.88 |
- GlobeNewswire•3 days ago
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Civitas, Entegra, and Immune Design on Behalf of Stockholders and Encourages Investors to Contact the Firm
NEW YORK, March 20, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Civitas Solutions, Inc.,.
- GlobeNewswire•5 days ago
IMMUNE DESIGN CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger
WILMINGTON, Del., March 18, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Immune Design Corp. (NASDAQ GM: IMDZ)?Did you purchase any of your shares prior to.
- PR Newswire•18 days ago
INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition
NEW YORK , March 5, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
- Zacks•26 days ago
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie
- Zacks•29 days ago
Merck to Buy Immunotherapy Developer Immune Design for $300M
Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
- ACCESSWIRE•29 days ago
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Immune Design Corp. - IMDZ
BALA CYNWYD, PA / ACCESSWIRE / February 22, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Immune Design Corp. ("Immune ...
- ACCESSWIRE•29 days ago
Healthcare Stocks Leading the Sector
HENDERSON, NV / ACCESSWIRE / February 22, 2019 / Below are several healthcare companies in the news leading the sector recently. A company in the sector that has not had news recently but according to ...
- GlobeNewswire•29 days ago
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Immune Design Corp. (IMDZ) on Behalf of Stockholders and Encourages IMDZ Investors to Contact the Firm
NEW YORK, Feb. 22, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Immune Design Corp. (NASDAQ: IMDZ) on behalf of.
- Zacks•29 days ago
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
- Benzinga•29 days ago
The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 21.) Eli Lilly And Co (NYSE: LLY ) Gossamer ...
- Investor's Business Daily•last month
Merck Plans $300 Million Acquisition Of Vaccine-Focused Biotech
Dow Jones component Merck, in an effort to bolster its vaccine offerings, will spend $300 million to buy Immune Design. Immune Design stock flew more than 300% as Merck rose a fraction.
- PR Newswire•last month
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp.
NEW YORK , Feb. 21, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Immune Design Corp. (NASDAQ: IMDZ) and its board of directors for breach of fiduciary duty concerning ...
- PR Newswire•last month
SHAREHOLDER ALERT: WeissLaw LLP Investigates Immune Design Corp.
NEW YORK , Feb. 21, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Immune Design Corp. ("IMDZ" ...
- GlobeNewswire•last month
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders
NEW YORK, Feb. 21, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Immune Design Corp. (“Immune Design”.
- Benzinga•last month
Merck To Buy Immune Design For $300M
Biotech M&A is on a roll in 2019, with a couple of multi-billion dollar deals announced already, including Bristol-Myers Squibb Co (NYSE: BMY )'s proposed buy of Celgene Corporation (NASDAQ: CELG ) and ...
- ACCESSWIRE•last month
Tech Stocks to Watch Today
CORAL GABLES, FL / ACCESSWIRE / February 21, 2019 / The recent success of the healthcare stock market can be attributed to the fact that companies in the healthcare industry are looking into new innovative approaches and technologies to better improve their offerings for consumers. Whereas cannabis was previously condemned as a harmful substance, medical experts have released studies showing that medicinal cannabis can be used to reduce inflammation caused by inflammatory diseases, as well as help patients suffering from acute anxiety, and countless other uses. In addition to the medical field shifting towards accepting medicinal cannabis, the healthcare sector, overall, has placed more emphasis on investing in the patient and their quality of life.
- PR Newswire•last month
Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal?
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immune Design Corp. (NASDAQ: IMDZ) ("Immune ...
- Reuters•last month
Merck to buy immunotherapy developer Immune Design for $300 mln
Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs. Merck will pay $5.85 in cash for each share of Immune ...
- Business Wire•last month
Merck to Acquire Immune Design
Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer
- Simply Wall St.•3 months ago
What Investors Should Know About Immune Design Corp.’s (NASDAQ:IMDZ) Financial Strength
The direct benefit for Immune Design Corp. (NASDAQ:IMDZ), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
- GlobeNewswire•4 months ago
Detailed Research: Economic Perspectives on NanoString Technologies, Tyson Foods, Welbilt, Immune Design, Turning Point Brands, and LGI Homes — What Drives Growth in Today's Competitive Landscape
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab
In the 26 naïve and relapsed/refractory patients in the randomized trial, the data continue to support the clinical activity of G100, with overall response rates of 46% and 23% in patients receiving a G100 regimen that includes low-dose radiation, with or without pembrolizumab, respectively. Also, disease control was shown in 92% and 85% of patients treated with the G100 regimen with or without pembrolizumab, respectively. In addition, responses appeared to be durable, with overall progression free survival at 11.1 or 7.4 months in patients treated with the G100 regimen with or without pembrolizumab, respectively.
- GlobeNewswire•4 months ago
Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today.
